Loading

Please wait...

Yondelis

Generic Name: trabectedin (tra BEK te din)
Brand Names: Yondelis
Yondelis (trabectedin) is used to treat liposarcoma or leiomyosarcoma, two common subtypes of soft tissue sarcoma. Includes Yondelis side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Yondelis

Set your location
for drug prices near you

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Yondelis (trabectedin) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Yondelis is used to treat liposarcoma, a rare type of cancer that grows in fatty tissues of the body. Yondelis is also used to treat leiomyosarcoma, a rare fast-growing type of cancer that grows in many tissues of the body, including fat, muscle, bone, joints, and blood vessels. Yondelis is used to treat cancer that has spread to other parts of the body or cannot be treated with surgery. Learn more

Yondelis Side Effects

Yondelis Side Effects

Note: This document contains side effect information about trabectedin. Some of the dosage forms listed on this page may not apply to the brand name Yondelis.

In Summary

Common side effects of Yondelis include: increased creatine phosphokinase in blood specimen, increased liver enzymes, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin, and neutropenia. Other side effects include: febrile neutropenia, cardiomyopathy, and fever. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to trabectedin: intravenous powder for solution

Along with its needed effects, trabectedin (the active ingredient contained in Yondelis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking trabectedin:

More common

  • Chest discomfort or pain
  • difficulty breathing
  • dizziness
  • faintness
  • fast irregular or pounding heartbeat
  • swelling of the feet or lower legs
  • unusual tiredness or weakness

Less common

  • Dark-colored urine
  • fever
  • muscle cramps or spasms
  • muscle pain or stiffness

Rare

  • Abdominal or stomach pain or tenderness
  • clay colored stools
  • decreased appetite
  • headache
  • itching or skin rash
  • loss of appetite
  • nausea and vomiting
  • swelling of the feet or lower legs
  • yellow eyes or skin

Incidence not known

  • Black, tarry stools
  • chills
  • cough
  • difficulty with swallowing
  • hives
  • lower back or side pain
  • painful or difficult urination
  • pale skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • sore throat
  • tightness in the chest
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising

Some side effects of trabectedin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Diarrhea
  • difficulty having a bowel movement (stool)
  • decreased appetite
  • headache
  • trouble sleeping

Incidence not known

  • Pain at the injection site

For Healthcare Professionals

Applies to trabectedin: intravenous powder for injection

Hepatic

Very common (10% or more): Increased ALT (up to 96.1%), increased AST (up to 89.5%), increased alkaline phosphatase (up to 70%), hyperbilirubinemia (up to 25.2%), increased gamma-glutamyltransferase (% unavailable)

Common (1% to 10%): Drug-induced liver injury

Uncommon (0.1% to 1%): Hepatotoxicity

Frequency not reported: Hepatic failure, increased conjugated bilirubin

Hematologic

Very common (10% or more): Anemia (up to 96%), neutropenia (up to 91.6%), leukopenia (up to 94.9%), thrombocytopenia (up to 63.7%)

Common (1% to 10%): Febrile neutropenia, neutropenic sepsis, pancytopenia, bone marrow failure, granulocytopenia

Uncommon (0.1% to 1%): Neutropenic infection

Gastrointestinal

Very common (10% or more): Nausea (up to 75%), vomiting (up to 51.7%), constipation (up to 37%), diarrhea (up to 35%), stomatitis (up to 19.2%),

Common (1% to 10%): Abdominal pain, dyspepsia, upper abdominal pain

Other

Very common (10% or more): Fatigue/asthenia/malaise (up to 69%), peripheral edema (up to 28%), mucosal inflammation (up to 11.4%), pyrexia (up to 10.2%)

Common (1% to 10%): Infection, edema, injection site reaction

Uncommon (0.1% to 1%): Septic shock

Frequency not reported: Multi-organ failure, catheter site reactions

Postmarketing reports: Extravasation/tissue necrosis

Metabolic

Very common (10% or more): Hypoalbuminemia (up to 63%), decreased appetite (up to 37%), anorexia (up to 28.8%)

Common (1% to 10%): Dehydration, hypokalemia, decreased weight

Renal

Very common (10% or more): Increased creatinine (up to 46%)

Common (1% to 10%): Renal failure

Musculoskeletal

Very common (10% or more): Elevated creatine phosphokinase (up to 33%), arthralgia (up to 15%), myalgia (up to 12%)

Common (1% to 10%): Back pain

Uncommon (0.1% to 1%): Rhabdomyolysis

Frequency not reported: Musculoskeletal pain

Respiratory

Very common (10% or more): Dyspnea (up to 25%)

Common (1% to 10%): Cough, pulmonary embolism

Uncommon (0.1% to 1%): Pulmonary edema

Nervous system

Very common (10% or more): Headache (up to 25%)

Common (1% to 10%): Peripheral neuropathy, dysgeusia, dizziness, paresthesia

Uncommon (0.1% to 1%): Syncope

Frequency not reported: Hypoesthesia

Dermatologic

Very common (10% or more): Palmar-plantar erythrodysesthesia (up to 24%), alopecia (up to 12%)

Common (1% to 10%): Rash, skin hyperpigmentation

Psychiatric

Very common (10% or more): Insomnia (up to 15%)

Cardiovascular

Common (1% to 10%): Cardiomyopathy, decreased ejection fraction, hypotension, flushing

Uncommon (0.1% to 1%): Left ventricular dysfunction

Hypersensitivity

Common (1% to 10%): Hypersensitivity reactions

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Yondelis (www.drugs.com/yondelis.html).